Literature DB >> 7684067

Characterization of two distinct monoclonal antibodies to paired helical filaments: further evidence for fetal-type phosphorylation of the tau in paired helical filaments.

M Hasegawa1, A Watanabe, K Takio, M Suzuki, T Arai, K Titani, Y Ihara.   

Abstract

Two monoclonal antibodies C5 and M4 raised against Sarkosyl-insoluble paired helical filaments (PHF) specifically labeled fetal tau, but hardly labeled normal adult tau. C5 immunoreactivity was eliminated by alkaline phosphatase treatment at 37 degrees C, whereas M4 reactivity could be removed only by the treatment at 67 degrees C. Epitope analysis showed that C5 and M4 recognition sites are in residues 386-406 and 198-250, respectively, according to the numbering of the longest human tau isoform. Thus, the phosphorylation sites are located in the amino- and carboxyl-terminal portions of the microtubule-binding region. These two well-characterized monoclonals should be valuable in the identification of a protein kinase(s) that converts normal tau into PHF-tau.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684067     DOI: 10.1111/j.1471-4159.1993.tb03491.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  23 in total

1.  Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Authors:  N Matsumura; T Yamazaki; Y Ihara
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics.

Authors:  T Iwatsubo; M Hasegawa; Y Ihara
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 3.  Changes in the ageing brain in health and disease.

Authors:  B H Anderton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

4.  Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain.

Authors:  T J Singh; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  Mol Cell Biochem       Date:  1996-01-26       Impact factor: 3.396

5.  Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation.

Authors:  T Miyasaka; M Morishima-Kawashima; R Ravid; P Heutink; J C van Swieten; K Nagashima; Y Ihara
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level.

Authors:  Amitabha Sengupta; Michal Novak; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2006-10-05       Impact factor: 4.124

7.  Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease.

Authors:  T Iwatsubo; H Yamaguchi; M Fujimuro; H Yokosawa; Y Ihara; J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

8.  Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease.

Authors:  Hitoshi Tanimukai; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

9.  Tau protein immunoreactivity in muscle fibers with rimmed vacuoles differs from that in regenerating muscle fibers.

Authors:  N Murakami; K Ishiguro; Y Ihara; I Nonaka; H Sugita; K Imahori
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5.

Authors:  A Sengupta; Q Wu; I Grundke-Iqbal; K Iqbal; T J Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.